
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


vTv Therapeutics Inc (VTVT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VTVT (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $35.5
1 Year Target Price $35.5
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.98% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.04M USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 2 | Beta 0.57 | 52 Weeks Range 12.62 - 26.99 | Updated Date 08/15/2025 |
52 Weeks Range 12.62 - 26.99 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -150717.64% |
Management Effectiveness
Return on Assets (TTM) -43.93% | Return on Equity (TTM) -209.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14200389 | Price to Sales(TTM) 2355.5 |
Enterprise Value 14200389 | Price to Sales(TTM) 2355.5 | ||
Enterprise Value to Revenue 835.32 | Enterprise Value to EBITDA -2.11 | Shares Outstanding 2617220 | Shares Floating 2222016 |
Shares Outstanding 2617220 | Shares Floating 2222016 | ||
Percent Insiders 35.6 | Percent Institutions 22.11 |
Upturn AI SWOT
vTv Therapeutics Inc

Company Overview
History and Background
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing orally administered small molecule drug candidates to treat a range of human diseases. Founded in 2015, the company focuses on diseases where unmet medical needs are high.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and potential commercialization of novel therapeutics.
Leadership and Structure
Details on leadership team and organizational structure are not readily available in detail.
Top Products and Market Share
Key Offerings
- TTP399: An oral small molecule designed to activate glucokinase in the liver and pancreas. Clinical trials are ongoing for Type 1 diabetes (T1D). Market share data is not available as it is in clinical trials. Competitors include companies developing novel diabetes therapies, such as Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with companies vying to develop innovative treatments for various diseases. It is heavily regulated and requires substantial investment in research and development.
Positioning
vTv Therapeutics Inc. is a small, clinical-stage company with a focus on diabetes. It aims to differentiate itself through its novel glucokinase activator, TTP399.
Total Addressable Market (TAM)
The global diabetes market is substantial, projected to reach hundreds of billions of dollars. vTv Therapeutics is positioned to capture a share of this market if TTP399 proves successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel glucokinase activator (TTP399)
- Focus on unmet needs in diabetes
- Experienced management team
Weaknesses
- Reliance on a single key drug candidate (TTP399)
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results for TTP399
- Partnerships with larger pharmaceutical companies
- Expansion into other therapeutic areas
Threats
- Clinical trial failures
- Competition from established diabetes therapies
- Regulatory hurdles
- Inability to raise additional capital
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
Competitive Landscape
vTv Therapeutics Inc. is a small player compared to established pharmaceutical giants. Its success hinges on the unique value proposition of TTP399.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely dependent on clinical trial progress and investor sentiment.
Future Projections: Future growth is highly dependent on the success of TTP399 in clinical trials. Analyst estimates will be highly variable.
Recent Initiatives: Recent initiatives likely revolve around advancing TTP399 through clinical trials and seeking partnerships.
Summary
vTv Therapeutics is a high-risk, high-reward clinical-stage biotech focused on developing TTP399 for diabetes. Its success depends on positive clinical trial results and securing funding or partnerships. The company faces significant competition from established pharmaceutical companies and is susceptible to regulatory and financial risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market data providers
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About vTv Therapeutics Inc
Exchange NASDAQ | Headquaters High Point, NC, United States | ||
IPO Launch date 2015-07-30 | CEO, President & Chairman of the Board Mr. Paul J. Sekhri M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://vtvtherapeutics.com |
Full time employees 23 | Website https://vtvtherapeutics.com |
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.